1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. RNA Interference Technology Market, by Type
6.1. Introduction
6.2. dsRNA
6.3. miRNA
6.4. siRNA

7. RNA Interference Technology Market, by Therapeutics
7.1. Introduction
7.2. Autoimmune Hepatitis
7.3. Hepatitis B and C
7.4. Neurological Disorders
7.5. Oncology

8. RNA Interference Technology Market, by Application
8.1. Introduction
8.2. Drug Discovery and Development
8.3. Therapeutics
8.3.1. Autoimmune Hepatitis
8.3.2. Hepatitis B and C
8.3.3. Neurological Disorders
8.3.4. Oncology
8.3.5. Respiratory Disorders

9. California RNA Interference Technology Market

10. Florida RNA Interference Technology Market

11. Illinois RNA Interference Technology Market

12. New York RNA Interference Technology Market

13. Ohio RNA Interference Technology Market

14. Pennsylvania RNA Interference Technology Market

15. Texas RNA Interference Technology Market

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Alnylam Pharmaceuticals Inc.
17.2. Ambion, Inc
17.3. Arcturus Therapeutics
17.4. Arrowhead Pharmaceuticals, Inc.
17.5. AstraZeneca plc
17.6. Atalanta Therapeutics
17.7. Bioneer Corporation
17.8. CureVac AG
17.9. Dicerna Pharmaceuticals
17.10. Gotham Therapeutics Corp.
17.11. Gradalis, Inc.
17.12. Invitrogen
17.13. Ionis Pharmaceuticals
17.14. Ionis Pharmaceuticals, Inc.
17.15. Merck KGaA
17.16. Phio Pharmaceuticals Inc.
17.17. Qiagen NV
17.18. Quark Pharmaceuticals, Inc.
17.19. Sanofi S.A.
17.20. Silence Therapeutics
17.21. Sirnaomics, Inc.
17.22. Thermo Fisher Scientific Inc.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: MARKET DYNAMICS
FIGURE 4. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 5. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2026
FIGURE 7. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DSRNA, 2018-2026 (USD MILLION)
FIGURE 8. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DSRNA, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 9. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MIRNA, 2018-2026 (USD MILLION)
FIGURE 10. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MIRNA, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 11. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SIRNA, 2018-2026 (USD MILLION)
FIGURE 12. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SIRNA, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 13. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2020 VS 2026 (%)
FIGURE 14. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2020 VS 2026 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2026
FIGURE 16. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, 2018-2026 (USD MILLION)
FIGURE 17. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 18. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, 2018-2026 (USD MILLION)
FIGURE 19. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 20. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2026 (USD MILLION)
FIGURE 21. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 22. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2026 (USD MILLION)
FIGURE 23. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 24. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 25. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2026
FIGURE 27. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2018-2026 (USD MILLION)
FIGURE 28. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 29. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD MILLION)
FIGURE 30. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 31. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, 2018-2026 (USD MILLION)
FIGURE 32. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 33. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, 2018-2026 (USD MILLION)
FIGURE 34. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 35. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2026 (USD MILLION)
FIGURE 36. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 37. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, 2018-2026 (USD MILLION)
FIGURE 38. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 39. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2026 (USD MILLION)
FIGURE 40. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESPIRATORY DISORDERS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 41. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: FPNV POSITIONING MATRIX
FIGURE 42. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 43. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DSRNA, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MIRNA, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SIRNA, BY STATE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY STATE, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY STATE, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY STATE, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 14. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY STATE, 2018-2026 (USD MILLION)
TABLE 15. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY STATE, 2018-2026 (USD MILLION)
TABLE 16. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY STATE, 2018-2026 (USD MILLION)
TABLE 17. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY STATE, 2018-2026 (USD MILLION)
TABLE 18. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY STATE, 2018-2026 (USD MILLION)
TABLE 19. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY STATE, 2018-2026 (USD MILLION)
TABLE 20. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESPIRATORY DISORDERS, BY STATE, 2018-2026 (USD MILLION)
TABLE 21. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: SCORES
TABLE 22. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: BUSINESS STRATEGY
TABLE 23. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: PRODUCT SATISFACTION
TABLE 24. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: RANKING
TABLE 25. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 26. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: MERGER & ACQUISITION
TABLE 27. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 28. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 29. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: INVESTMENT & FUNDING
TABLE 30. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 31. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET: LICENSE & PRICING

Companies Mentioned

Alnylam Pharmaceuticals Inc.
Ambion, Inc
Arcturus Therapeutics
Arrowhead Pharmaceuticals, Inc.
AstraZeneca plc
Atalanta Therapeutics
Bioneer Corporation
CureVac AG
Dicerna Pharmaceuticals
Gotham Therapeutics Corp.
Gradalis, Inc.
Invitrogen
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc.
Merck KGaA
Phio Pharmaceuticals Inc.
Qiagen NV
Quark Pharmaceuticals, Inc.
Sanofi S.A.
Silence Therapeutics
Sirnaomics, Inc.
Thermo Fisher Scientific Inc.